Targeted therapy with nanatinostat and valganciclovir in recurrent EBV-positive lymphoid malignancies: a phase 1b/2 study (2023)
- Authors:
- Autor USP: PEREIRA, JULIANA - FM
- Unidade: FM
- DOI: 10.1182/bloodadvances.2023010330
- Subjects: LINFOMA; INFECÇÕES POR VÍRUS DE DNA; INIBIDORES DE ENZIMAS; APOPTOSE
- Agências de fomento:
- Language: Inglês
- Imprenta:
- Source:
- Título: Blood advances
- ISSN: 2473-9529
- Volume/Número/Paginação/Ano: v. 7, n. 20, p. 6339-6350, 2023
- Status:
- Artigo publicado em periódico de acesso aberto (Gold Open Access)
- Versão do Documento:
- Versão publicada (Published version)
- Acessar versão aberta:
-
ABNT
HAVERKOS, Bradley et al. Targeted therapy with nanatinostat and valganciclovir in recurrent EBV-positive lymphoid malignancies: a phase 1b/2 study. Blood advances, v. 7, n. 20, p. 6339-6350, 2023Tradução . . Disponível em: https://observatorio.fm.usp.br/handle/OPI/57344. Acesso em: 02 abr. 2026. -
APA
Haverkos, B., Alpdogan, O., Baiocchi, R., Brammer, J. E., Feldman, T. A., Capra, M., et al. (2023). Targeted therapy with nanatinostat and valganciclovir in recurrent EBV-positive lymphoid malignancies: a phase 1b/2 study. Blood advances, 7( 20), 6339-6350. doi:10.1182/bloodadvances.2023010330 -
NLM
Haverkos B, Alpdogan O, Baiocchi R, Brammer JE, Feldman TA, Capra M, Brem EA, Nair S, Scheinberg P, Pereira J. Targeted therapy with nanatinostat and valganciclovir in recurrent EBV-positive lymphoid malignancies: a phase 1b/2 study [Internet]. Blood advances. 2023 ; 7( 20): 6339-6350.[citado 2026 abr. 02 ] Available from: https://observatorio.fm.usp.br/handle/OPI/57344 -
Vancouver
Haverkos B, Alpdogan O, Baiocchi R, Brammer JE, Feldman TA, Capra M, Brem EA, Nair S, Scheinberg P, Pereira J. Targeted therapy with nanatinostat and valganciclovir in recurrent EBV-positive lymphoid malignancies: a phase 1b/2 study [Internet]. Blood advances. 2023 ; 7( 20): 6339-6350.[citado 2026 abr. 02 ] Available from: https://observatorio.fm.usp.br/handle/OPI/57344 - Adult T-Cell Leukemia/Lymphoma: A Clinical and Epidemiological Analysis at the Medicine School of Sao Paulo University
- How to manage lymphoid malignancies during novel 2019 coronavirus (CoVid-19) outbreak: a Brazilian task force recommendation
- Radiographic patterns of multiple myeloma in the jawbones of patients treated with intravenous bisphosphonates
- GATA-3 is a proto-oncogene in T-cell lymphoproliferative neoplasms
- Comparison of Subcutaneous Versus Intravenous Administration of Rituximab As Maintenance Treatment for Follicular Lymphoma: Results From a Two-Stage, Phase IB Study
- Panoramic and skull imaging may aid in the identification of multiple myeloma lesions
- Estudo de células precuroras em leucemias agudas: identificação e fator de prognóstico das proteínas Bcl-2, Bax e CD95/Fas/APO-1
- 18 F-FDG pet interim and determination of cellular origin by immunohistochemistry identify a group of very good prognosis in patients with diffuse large B cell lymphoma in the rituximab era
- Immune reconstitution inflammatory syndrome-associated lymphoma: a retrospective Brazilian cohort
- Macrophage migration inhibitory factor and chemokine RANTES in young pediatric patients with congenital cardiac communications: relation to hemodynamic parameters and the presence of Down syndrome
Informações sobre a disponibilidade de versões do artigo em acesso aberto coletadas automaticamente via oaDOI API (Unpaywall).
Por se tratar de integração com serviço externo, podem existir diferentes versões do trabalho (como preprints ou postprints), que podem diferir da versão publicada.
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
